263 related articles for article (PubMed ID: 33550238)
1. Comparative efficacy and safety of different regimens of ranibizumab for neovascular age-related macular degeneration: a network meta-analysis of randomised controlled trials.
Zhao X; Meng L; Chen Y
BMJ Open; 2021 Feb; 11(2):e040906. PubMed ID: 33550238
[TBL] [Abstract][Full Text] [Related]
2. Treatment regimens for administration of anti-vascular endothelial growth factor agents for neovascular age-related macular degeneration.
Li E; Donati S; Lindsley KB; Krzystolik MG; Virgili G
Cochrane Database Syst Rev; 2020 May; 5(5):CD012208. PubMed ID: 32374423
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of different agents, dosages and strategies of anti-vascular endothelial growth factor treatment for neovascular age-related macular degeneration: a network meta-analysis of randomized controlled trials.
Zhao XY; Meng LH; Liu SZ; Chen YX
Acta Ophthalmol; 2021 Nov; 99(7):e1041-e1050. PubMed ID: 33438364
[TBL] [Abstract][Full Text] [Related]
4. A randomised controlled trial to assess the clinical effectiveness and cost-effectiveness of alternative treatments to Inhibit VEGF in Age-related choroidal Neovascularisation (IVAN).
Chakravarthy U; Harding SP; Rogers CA; Downes S; Lotery AJ; Dakin HA; Culliford L; Scott LJ; Nash RL; Taylor J; Muldrew A; Sahni J; Wordsworth S; Raftery J; Peto T; Reeves BC
Health Technol Assess; 2015 Oct; 19(78):1-298. PubMed ID: 26445075
[TBL] [Abstract][Full Text] [Related]
5. Anti-vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion.
Mitry D; Bunce C; Charteris D
Cochrane Database Syst Rev; 2013 Jan; (1):CD009510. PubMed ID: 23440840
[TBL] [Abstract][Full Text] [Related]
6. Comparative Efficacy, Durability and Safety of Faricimab in the Treatment of Diabetic Macular Edema: A Systematic Literature Review and Network Meta-Analysis.
Watkins C; Paulo T; Bührer C; Holekamp NM; Bagijn M
Adv Ther; 2023 Dec; 40(12):5204-5221. PubMed ID: 37751021
[TBL] [Abstract][Full Text] [Related]
7. Real-World Effectiveness and Real-World Cost-Effectiveness of Intravitreal Aflibercept and Intravitreal Ranibizumab in Neovascular Age-Related Macular Degeneration: Systematic Review and Meta-Analysis of Real-World Studies.
Carrasco J; Pietsch GA; Nicolas MP; Koerber C; Bennison C; Yoon J
Adv Ther; 2020 Jan; 37(1):300-315. PubMed ID: 31728825
[TBL] [Abstract][Full Text] [Related]
8. Treat and extend versus fixed regimen in neovascular age related macular degeneration: A systematic review and meta-analysis.
Fallico M; Lotery AJ; Longo A; Avitabile T; Bonfiglio V; Russo A; Castellino N; Parisi G; Pulvirenti A; Eandi C; Cennamo G; Furino C; Cicinelli MV; Alovisi C; Reibaldi M
Eur J Ophthalmol; 2021 Sep; 31(5):2496-2504. PubMed ID: 33118382
[TBL] [Abstract][Full Text] [Related]
9. Comparative efficacy and safety of anti-vascular endothelial growth factor regimens for neovascular age-related macular degeneration: systematic review and Bayesian network meta-analysis.
Ye L; Jiaqi Z; Jianchao W; Zhaohui F; Liang Y; Xiaohui Z
Ther Adv Chronic Dis; 2020; 11():2040622320953349. PubMed ID: 32953000
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of a Treat-and-Extend Regimen With Ranibizumab in Patients With Neovascular Age-Related Macular Disease: A Randomized Clinical Trial.
Kertes PJ; Galic IJ; Greve M; Williams G; Baker J; Lahaie M; Sheidow T
JAMA Ophthalmol; 2020 Mar; 138(3):244-250. PubMed ID: 31917441
[TBL] [Abstract][Full Text] [Related]
11. One-year outcome of ranibizumab for neovascular age-related macular degeneration: a thorough analysis in a real-world clinical setting.
Gabai A; Veritti D; Lanzetta P
Eur J Ophthalmol; 2014; 24(3):396-401. PubMed ID: 24242222
[TBL] [Abstract][Full Text] [Related]
12. Treat and Extend versus Pro Re Nata regimens of ranibizumab in neovascular age-related macular degeneration: a comparative 12 Month study.
Hatz K; Prünte C
Acta Ophthalmol; 2017 Feb; 95(1):e67-e72. PubMed ID: 27009503
[TBL] [Abstract][Full Text] [Related]
13. A randomised, double-masked, controlled study of the efficacy and safety of intravitreal bevacizumab versus ranibizumab in the treatment of macular oedema due to branch retinal vein occlusion: MARVEL Report No. 1.
Narayanan R; Panchal B; Das T; Chhablani J; Jalali S; Ali MH;
Br J Ophthalmol; 2015 Jul; 99(7):954-9. PubMed ID: 25631483
[TBL] [Abstract][Full Text] [Related]
14. Comparative efficacy of bevacizumab, ranibizumab, and aflibercept for treatment of macular edema secondary to retinal vein occlusion: a systematic review and network meta-analysis.
Sangroongruangsri S; Ratanapakorn T; Wu O; Anothaisintawee T; Chaikledkaew U
Expert Rev Clin Pharmacol; 2018 Sep; 11(9):903-916. PubMed ID: 30071180
[TBL] [Abstract][Full Text] [Related]
15. Intravitreal Bevacizumab Versus Ranibizumab for Treatment of Neovascular Age-Related Macular Degeneration: Findings from a Cochrane Systematic Review.
Solomon SD; Lindsley KB; Krzystolik MG; Vedula SS; Hawkins BS
Ophthalmology; 2016 Jan; 123(1):70-77.e1. PubMed ID: 26477843
[TBL] [Abstract][Full Text] [Related]
16. Comparative Efficacy of Pharmacotherapy for Macular Edema Secondary to Retinal Vein Occlusion: A Network Meta-analysis.
Gao S; Zhang Y; Li X; Ge G; Duan J; Lei C; Zeng Y; Cai Z; Zhang M
Front Pharmacol; 2021; 12():752048. PubMed ID: 34955825
[No Abstract] [Full Text] [Related]
17. Efficacy and safety of intravitreal aflibercept in ranibizumab-refractory patients with neovascular age-related macular degeneration.
Razavi S; Kodjikian L; Giocanti-Aurégan A; Dufour I; Souied E
BMC Ophthalmol; 2021 Feb; 21(1):90. PubMed ID: 33596867
[TBL] [Abstract][Full Text] [Related]
18. Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocol.
Berg K; Pedersen TR; Sandvik L; Bragadóttir R
Ophthalmology; 2015 Jan; 122(1):146-52. PubMed ID: 25227499
[TBL] [Abstract][Full Text] [Related]
19. Ranibizumab or Bevacizumab for Neovascular Age-Related Macular Degeneration According to the Lucentis Compared to Avastin Study Treat-and-Extend Protocol: Two-Year Results.
Berg K; Hadzalic E; Gjertsen I; Forsaa V; Berger LH; Kinge B; Henschien H; Fossen K; Markovic S; Pedersen TR; Sandvik L; Bragadóttir R
Ophthalmology; 2016 Jan; 123(1):51-9. PubMed ID: 26477842
[TBL] [Abstract][Full Text] [Related]
20. StereoTactic radiotherapy for wet Age-Related macular degeneration (STAR): study protocol for a randomised controlled clinical trial.
Neffendorf JE; Desai R; Wang Y; Kelly J; Murphy C; Reeves BC; Chakravarthy U; Wordsworth S; Lewis C; Peacock J; Uddin S; O'Sullivan JM; Jackson TL
Trials; 2016 Nov; 17(1):560. PubMed ID: 27881184
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
